Does Vitamin K2 Actually Slow Artery Calcification? What Two Real Trials Found

Vitamin K2 has become one of the most recommended supplements in longevity circles, usually attached to a simple pitch: it directs calcium to your bones instead of your arteries. The mechanism behind that claim is real. Vitamin K activates a protein called matrix Gla protein, which blocks calcium from building up in artery walls, a finding that goes back to a 1997 paper in Nature. The question worth testing is whether that mechanism actually shows up as less calcification in real people, tracked over real time.

Two trials have actually tried to answer that, both using CT scans to track coronary calcium score over two years, and both are worth reading in full rather than taking on faith.

The first, VitaK-CAC, followed 167 adults with mild existing calcium buildup (a score between 50 and 400), giving half of them 360 micrograms of K2 (as MK-7) alone, with no vitamin D added, against a placebo. After two years, calcium score rose by a median of 49 points in the K2 group and 69 points in the placebo group, a statistically meaningful difference. The second, DANCODE, followed 398 adults with more severe existing calcium (a score of 400 or higher), giving half of them a combination of 720 micrograms of K2 and 25 micrograms of D3 daily. Calcium score rose by 196 points on K2 plus D3 versus 248 points on placebo, 21% less progression, with no corresponding rise in non-calcified plaque.

Here's what neither trial can tell you. Both tracked a surrogate marker, calcium score, not actual heart attacks or deaths, and neither enrolled enough people or ran long enough to catch those events. The researchers who ran DANCODE said so themselves: they stated directly that they can't yet recommend K2 for this purpose, pending longer-term data on survival and clotting risk. Worth knowing too that DANCODE was funded by the maker of the K2 used in the trial, and VitaK-CAC was co-sponsored by a vitamin K research company, the kind of funding detail that doesn't invalidate the data but is worth weighing.

So where does that leave you. The mechanism is confirmed. The calcium-score slowdown is real and replicated across two separate trials. What's still unproven is whether slowing a number on a CT scan actually means fewer heart attacks, and that's a different, harder question these two trials weren't built to answer. If you're already taking K2, or considering it, that's a reasonable place to start, paired with an actual coronary calcium scan of your own rather than guessing.

This is exactly the kind of claim functional lab testing is built for: not taking a supplement's reputation at face value, but checking what your own numbers are actually doing. If you want to find out where you're starting from, book a free discovery call and we'll talk through what's actually worth testing for you.